Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine

AIDS

Volumn 15, Issue 18, 2001, Pages 2423-2429

  Wit, F W N M ^a   Wood, R ^a   Horban, A ^a   Beniowski, M ^a   Schmidt, R E ^a   Gray, G ^a   Lazzarin, A ^a   Lafeuillade, A ^a   Paes, D ^a   Carlier, H ^a   Van Weert, L ^a   De Vries, C ^a   Van Leeuwen, R ^a   Lange, J M A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Abacavir; HIV 1; Hypersensitivity reaction; Nevirapine; Prednisolone; Rash; Toxicity

Indexed keywords

ABACAVIR; LAMIVUDINE; NEVIRAPINE; PREDNISOLONE; ZIDOVUDINE;

ADJUVANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTI-INFLAMMATORY AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; PREDNISOLONE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035824722     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200112070-00010     Document Type: Article

References (31)

1. Adverse effects of antiretroviral therapy
2. HIV-1 infected patients with toxic epidermal necrolysis: An occupational risk for healthcare workers
3. Nevirapine and rashes
4. Nevirapine-associated Stevens-Johnson syndrome
5. Anaphylaxis after rechallenge with abacavir
6. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction
7. Severe hypersensitivity reactions following reintroduction of abacavir
8. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
9. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection
10. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients
11. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
12. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication
13. Experience with nevirapine in previously treated HIV-1-infected individuals. Dutch HIV-treating physicians
14. Sex differences in nevirapine rash
15. Severe hepatic failure related to nevirapine treatment
16. Nevirapine-induced hepatitis treated with corticosteroids?
17. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects
18. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
19. Abacavir
20. Management protocol for abacavir-related hypersensitivity reaction
21. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial
22. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group
23. Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole during treatment of AIDS-associated Pneumocystis carinii pneumonia
24. Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS: A randomized European multicenter open label study
25. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids
26. Prevention of nevirapine-associated rash
27. Prednisolone therapy during the induction phase of nevirapine therapy appears to reduce the incidence of nevirapine-associated rash
28. Prednisolone does not prevent the occurrence of nevirapine-induced rashes
29. The effects of a short course of prednisolone on the incidence of rash associated with nevirapine
30. Gender, use of corticosteroids and CD4 counts are predictive factors of nevirapine-associated rash